NOD2 downregulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6

T Watanabe1,2,3,7, N Asano2,4,7, G Meng2, K Yamashita5, Y Arai5, T Sakurai6, M Kudo6, IJ Fuss2, A Kitani2, T Shimosegawa4, T Chiba3 and W Strober2

It is well established that polymorphisms of the caspase activation and recruitment domain 15 (CARD15) gene, a major risk factor in Crohn’s disease (CD), lead to loss of nucleotide-binding oligomerization domain 2 (NOD2) function. However, a molecular explanation of how such loss of function leads to increased susceptibility to CD has remained unclear. In a previous study exploring this question, we reported that activation of NOD2 in human dendritic cells by its ligand, muramyl dipeptide (MDP), negatively regulates Toll-like receptor (TLR)-mediated inflammatory responses. Here we show that NOD2 activation results in increased interferon regulatory factor 4 (IRF4) expression and binding to tumor necrosis factor receptor associated factor 6 (TRAF6) and RICK (receptor interacting serine–threonine kinase). We then show that such binding leads to IRF4-mediated inhibition of Lys63-linked polyubiquitination of TRAF6 and RICK and thus to downregulation of nuclear factor (NF)-κB activation. Finally, we demonstrate that protection of mice from the development of experimental colitis by MDP or IRF4 administration is accompanied by similar IRF4-mediated effects on polyubiquitination of TRAF6 and RICK in colonic lamina propria mononuclear cells. These findings thus define a mechanism of NOD2-mediated regulation of innate immune responses to intestinal microflora that could explain the relation of CARD15 polymorphisms and resultant NOD2 dysfunction to CD.

INTRODUCTION

Nucleotide-binding oligomerization domain 2 (NOD2) is a NOD-like receptor (NLR) family member that functions as an intracellular sensor of small peptides (such as muramyl dipeptide (MDP)) derived from the peptidoglycan component of the bacterial cell wall.1,2 Activation of NOD2 occurring upon sensing of its ligand through its leucine-rich repeat domain is followed by NOD2 oligomerization and exposure of its caspase activation and recruitment domain (CARD). This enables a physical interaction between NOD2 and a downstream adaptor molecule, receptor interacting serine–threonine kinase (RICK) that then results in lysine 63 (K63)-linked polyubiquitination of RICK.1–3 Ubiquitinated RICK then interacts with transforming growth factor-β-activated kinase 1 and tumor necrosis factor receptor associated factor 6 (TRAF6) to cause nuclear translocation of nuclear factor (NF)-κB subunits.4–8

The functional importance of NOD2 is underscored by the fact that polymorphisms in the CARD15 gene encoding NOD2 are associated with Crohn’s disease (CD) and other immune disorders such as graft versus host disease.1,2,9 However, despite extensive investigation, the molecular mechanisms by which such polymorphisms contribute to these diseases are not completely understood.1,9 A possible clue to the nature of these mechanisms comes from the fact that MDP activation of NOD2 can both positively and negatively regulate Toll-like receptor (TLR)-mediated inflammatory responses. For example, synergistic production of proinflammatory cytokine responses has been observed in human antigen-presenting cells (APCs) upon
simultaneous stimulation of MDP and TLR ligands.\textsuperscript{10,11} This synergism could contribute to the control of the gastrointestinal commensal microflora that is necessary for the prevention of CD.\textsuperscript{12}

However, the above described capacity of NOD2 activation to augment innate immune responses is accompanied by the fact that such activation also has a negative effect on TLR signaling. Thus, we and others have shown that preactivation of NOD2 by MDP induces decreased proinflammatory cytokine responses in human APCs upon subsequent challenge with TLR ligands.\textsuperscript{13–17} In addition, Hedl \textit{et al.}\textsuperscript{15,16} have shown that such tolerogenic responses were not observed in human APCs from patients bearing CD-associated NOD2 mutations.\textsuperscript{17} We have also found that systemic injection of MDP protects NOD2-intact mice from experimental colitis, but not NOD2- or RICK-deficient mice.\textsuperscript{6,14,18} Collectively, these data support the idea that MDP activation of NOD2 downregulates innate immune responses to intestinal microflora and thus suggest that the absence of such regulation leads to increased susceptibility to CD.

In a previous study, we showed that MDP prestimulation of NOD2 regulation of TLR response, we showed that MDP activation of NOD2 induces interferon regulatory factor 4 (IRF4) in human dendritic cells (DCs) and that such induction is necessary for the negative regulation of subsequent TLR-induced proinflammatory responses.\textsuperscript{14} In this study, we report that following NOD2 activation, IRF4 interacts with myeloid differentiation factor 88 (MyD88), TRAF6, and RICK and downregulates K63-linked polyubiquitinylation of RICK and TRAF6; this, in turn, disrupts NOD2- and TLR–MyD88-induced NF-κB activation pathways, respectively. Thus, IRF4 function initiated by NOD2 activation provides new insight into how NOD2 influences colitis and why loss-of-function CARD15 polymorphisms serve as a risk factor in CD.

**RESULTS**

**Physical interactions between IRF4 and MyD88, RICK, and TRAF6 in human DCs**

In a previous study,\textsuperscript{14} we showed that NOD2 prestimulation of human DCs results in inhibition of subsequent TLR-induced cytokine responses and that such inhibition requires the upregulation of IRF4. As for the mechanism of this IRF4 effect, we found in overexpression studies that NOD2 downregulation of TLR-mediated NF-κB activation is associated with IRF4 interaction with MyD88, RICK, and TRAF6; thus, it appeared that IRF4 was interfering with TLR signaling in some manner.

In this study, we addressed the molecular basis of this NOD2–IRF4 inhibitory mechanism by first assessing NOD2-induced IRF4 physical interaction with RICK, MyD88, and TRAF6 in human DCs under physiologic conditions. For this purpose, DCs derived from healthy control peripheral blood monocytes (obtained by culturing the latter in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)–4) were prestimulated with MDP for 24 h and then restimulated with MDP or lipopolysaccharide (LPS). As shown in Figure 1a, MDP prestimulation (designated in Figure 1 as first stimulation) upregulated endogenous IRF4 expression in human DCs without altering their constitutive expression of RICK, MyD88, or TRAF6.

Accompanying studies in which immunoprecipitation (IP) followed by immunoblotting (IB) was performed to assess signaling component interactions revealed that MDP pretreatment enhanced IRF4 binding to RICK, especially when it was accompanied by MDP restimulation. In addition, IRF4 binding to TRAF6 was barely seen in unstimulated cells or cells stimulated with MDP or LPS without pretreatment, but was clearly evident in cells prestimulated with MDP, especially when such pretreatment was followed by restimulation with MDP or LPS. Finally, IRF4 binding to MyD88 was increased in cells prestimulated with MDP and restimulated with LPS.

To verify the above IP–IB studies of interactions between IRF4 and various binding molecules in cells subjected to MDP stimulation, we employed the Duolink assay that allows fluorescent visualization of interacting proteins.\textsuperscript{19} As shown in Figure 1b, an IRF4–RICK complex was generated in both cells prestimulated with MDP and restimulated with MDP or LPS. In addition, IRF4–TRAF6 and IRF4–MyD88 complexes were generated in cells prestimulated with MDP and restimulated with either MDP or LPS, particularly the latter. Thus, both the IP–IB and Duolink assays reveal enhanced interactions between IRF4 and RICK, MyD88, and TRAF6 in human primary DCs prestimulated with MDP.

As also shown in Figure 1a, MDP prestimulation of cells was associated with reduced expression of phospho-IkBz and degradation of IkBz. Thus, the enhanced interaction between IRF4, RICK, and MyD88 in MDP-pretreated human DCs is associated with downregulation of the NF-κB signaling pathway.

**IRF4 with mutations at two known phosphorylation sites is capable of both RICK-IRF4 interaction and IRF4 negative regulation**

As RICK is a serine–threonine kinase, NOD2 activation of RICK could be regulating IRF4 function by enhancing RICK phosphorylation of IRF4. To investigate this possibility, we first determined the ability of RICK mutated at K47 (K47A) and/or S176 (S176A), sites previously shown to be necessary for RICK kinase activity.\textsuperscript{20,21} As shown in Figure 2a, binding of IRF4 to RICK (in proportion to RICK expression) was observed in 293 cells after the transfection of FLAG-tagged IRF4 along with RICK mutants lacking kinase activity.

In related studies, we determined the ability of IRF4 mutated at both S447 (S447A) and S448 (S448A), the potential serine phosphorylation sites previously shown to be necessary for IRF4 function in relation to IL-21 regulation, to bind to RICK.\textsuperscript{22} As shown in Figure 2b, both wild-type (WT) IRF4 and mutated IRF4 bound to RICK in 293 cells overexpressing V5-tagged RICK and FLAG-tagged IRF4. Thus, phosphorylation of IRF4 at these two potential phosphorylation sites was not required for the interaction between RICK and IRF4.

Finally, to assess the capacity of IRF4 lacking two serine phosphorylation sites to regulate NF-κB activity, we transfected
plasmids expressing either WT or mutated IRF4 into HT-29 cells (i.e., nonhematopoietic cells not likely to express endogenous IRF4) co-transfected with a RICK-expressing plasmid as well as an NF-κB luciferase reporter-expressing plasmid. As shown in Figure 2c, transfection with mutated IRF4 led to a significant reduction in RICK activation of NF-κB as compared with that of WT IRF4. In complementary studies to address the same question in TLR-stimulated cells, we transfected either WT or mutated IRF4 into human THP1 cells that lack expression of IRF4 either before or after stimulation with MDP, as shown in our previous study, and then cultured the cells with TLR2 ligand (Pam3CSK4, PAM) or TLR4 ligand (LPS) to determine their capacity to produce NF-κB-dependent cytokines. As shown in Figure 2d, transfection of mutated IRF4 into THP1 cells led to a significant decrease in TLR2 induction of IL-12p40 as compared with that of WT IRF4. Thus, these data provide evidence that loss of potential serine phosphorylation sites enhances increased IRF4-mediated negative regulation of NF-κB activation and its downstream effect on cytokine production.

IRF4 regulates Lys63-linked polyubiquitination of RICK

TLR and NOD-like receptor (NLR) activation of NF-κB requires K63 polyubiquitination of signaling components such as RICK and TRAF6. It was therefore possible that IRF4 expression induced by NOD2 activation inhibits NF-κB activation by downregulation of such polyubiquitination. To address this question, we first investigated the effect of IRF4 on RICK polyubiquitination in 293 cells transfected with plasmids expressing HA-tagged ubiquitin (Ub), V5-tagged RICK, and FLAG-tagged IRF4 and then lysed to obtain cell lysates that were subjected to IP with anti-HA antibody (Ab) and IB with anti-V5 Ab.

As shown in Figure 3a, polyubiquitination of RICK was seen in 293 cells expressing HA-tagged WT Ub and V5-tagged RICK alone but not in cells also expressing IRF4. Consistent with previous studies showing that the E3 ligases, TRAF6 and cellular inhibitors of apoptosis proteins (cIAPs), induce K63-linked polyubiquitination of RICK, co-transfection of plasmids expressing TRAF6 or cIAP1 or cIAP2 enhanced polyubiquitination of RICK; however, such enhanced...
polyubiquitination of RICK was also markedly reduced in cells expressing IRF4 (Figure 3a,b). In further studies to determine the linkage type of poly-Ub chains on RICK, 293 cells were transfected with plasmids expressing mutant forms of Ub that specifically ubiquitinate via either K48 or K63 linkages. As shown in Figure 3a (middle and right panels), 293 cells expressing IRF4 exhibited reduced K63-linked polyubiquitination of RICK, even in cells cotransfected with TRAF6 that expressed increased amounts of K63-polyubiquitinated RICK; however, IRF4 expression had little or no effect on the marginal amount of K48-linked polyubiquitination observed, even in the presence of TRAF6.

As shown in Figure 3b, enhanced K63-linked polyubiquitination of RICK induced by cIAP1 or cIAP2 (but not K48-linked polyubiquitination) was also inhibited in cells expressing IRF4, whereas K63-linked polyubiquitination of RICK by ITCH, another E3 ligase known to induce such polyubiquitination, was not reduced in cells expressing IRF4 (data not shown). In addition, as shown in Figure 3c, reduced RICK polyubiquitination was seen in cells expressing either WT IRF4 or mutated IRF4 lacking its phosphorylation site, indicating that the inhibitory effect of IRF4 was not dependent on its phosphorylation status. Finally, as shown in Figure 3d, polyubiquitination of RICK induced by 30 min of stimulation with MDP in 293 cells stably expressing NOD2 was barely seen upon cotransfection of IRF4; thus, the inhibitory effect of IRF4 also applies to RICK activated by NOD2.

In related studies we identified RICK domains that interact with IRF4 and that are necessary for IRF4 inhibition of polyubiquitination. RICK is composed of a kinase domain, an intermediate domain, and a CARD domain. We therefore transfected plasmids expressing V5-tagged RICK mutants lacking each of these domains as well as RICK fragments composed of each of these domains into 293 cells cotransfected...
with plasmids expressing FLAG-IRF4. As shown in Figure 4a, the interaction between RICK and IRF4 (defined by IP–IB studies) required the presence of the kinase and/or the intermediate RICK domains, as the interaction could be detected in 293 cells overexpressing kinase and intermediate domain RICK mutants but not in cells expressing the CARD domain mutant. Thus, the interaction between RICK and IRF4 was mediated by the binding of IRF4 to either the kinase or the intermediate domain but not to the CARD domain. With this information in hand, we next conducted ubiquitination studies of RICK domains in 293 cells transfected with plasmids expressing V5-RICK mutants or RICK fragments and cotransfected with plasmids expressing HA-Ub in the absence of IRF4 cotransfection. In previous studies, Hasegawa et al.7 showed that polyubiquitination of RICK at K209 in the kinase domain is essential for RICK-mediated NF-κB activation. As shown in Figure 4b, consistent with this finding, 293 cells overexpressing mutant RICK lacking the kinase domain exhibited grossly defective polyubiquitination, whereas those overexpressing RICK mutants lacking the intermediate or CARD domains still exhibited polyubiquitination, although less than that of WT RICK; in addition, as also shown in Figure 4b, whereas a kinase domain fragment of RICK was polyubiquitinated, an intermediate domain fragment of RICK was not. Thus, these studies demonstrate that the IRF4 inhibition of RICK polyubiquitination shown above involves polyubiquitination of the kinase domain of RICK, and this inhibition is facilitated by IRF4 binding to the kinase and/or intermediate domains of RICK.

**IRF4 regulates polyubiquitination of TRAF6**

Stimulation of the TLRs leads to the recruitment of MyD88 and TRAF6 to the receptor complex.27 This process activates...
TRAF6 E3 ligase activity and TRAF6-mediated K63-linked polyubiquitination of downstream target proteins as well as TRAF6 itself. As IRF4 binds to TRAF6 following MDP prestimulation, it seemed possible that, as in the case of RICK polyubiquitination, TRAF6 polyubiquitination was regulated by IRF4. To address this question, 293 cells were transfected with vectors expressing FLAG-tagged IRF4 and various forms of V5-tagged mutated RICK; whole-cell lysates were isolated 48 h after the transfection and were then subjected to immunoprecipitation (IP) with the indicated antibody (Ab) followed by immunoblotting (IB) with the indicated Ab. (b) The 293 cells were transfected with vectors expressing various forms of V5-tagged mutated RICK and HA-tagged ubiquitin (Ub); whole-cell lysates were isolated 48 h after the transfection and were subjected to IP with the indicated Ab followed by IB with the indicated Ab. Results shown are representative of two experiments. IRF4, interferon regulatory factor 4; RICK, receptor interacting serine–threonine kinase.

Figure 4 IRF4 inhibition of RICK polyubiquitination is facilitated by IRF4 binding to the kinase and/or intermediate domains of RICK. (a) The 293 cells were transfected with vectors expressing FLAG-tagged IRF4 and various forms of V5-tagged mutated RICK; whole-cell lysates were isolated 48 h after the transfection and were then subjected to immunoprecipitation (IP) with the indicated antibody (Ab) followed by immunoblotting (IB) with the indicated Ab. (b) The 293 cells were transfected with vectors expressing various forms of V5-tagged mutated RICK and HA-tagged ubiquitin (Ub); whole-cell lysates were isolated 48 h after the transfection and were subjected to IP with the indicated Ab followed by IB with the indicated Ab. Results shown are representative of two experiments. IRF4, interferon regulatory factor 4; RICK, receptor interacting serine–threonine kinase.

To this end, cell lysates prepared from human DCs that were prestimulated with MDP for 24 h and then restimulated with MDP or LPS were subjected to IP with Abs specific to K63- or K48-ubiquitin and then IB with Abs specific for RICK or TRAF6.

As shown in Figure 6a, prestimulation of human DCs with MDP greatly reduced K63-linked polyubiquitination of RICK upon secondary stimulation with MDP of human DCs. Similarly, prestimulation with MDP greatly reduced K63-linked but not K48-linked polyubiquitination of TRAF6 upon secondary stimulation with LPS. It should be noted that LPS stimulation did not induce K63-linked polyubiquitination of RICK, and MDP stimulation did not induce K63-linked polyubiquitination of TRAF6; thus, the possible effect of prestimulation of cells with MDP in these situations could not be evaluated.

To determine whether the negative effect of MDP prestimulation on K63-linked polyubiquitination was in fact due to IRF4, we next conducted studies of cells in which IRF4 was downregulated by IRF4-specific small interfering RNA (siRNA; Figure 6b). As shown in Figure 6c, whereas MDP prestimulation of cells again led to inhibition of MDP-stimulated RICK and LPS-stimulated TRAF6 K63-linked polyubiquitination, respectively, such inhibition was reversed in cells treated with IRF4 siRNA. These studies show that in

Prestimulation of human DCs with MDP inhibits Lys63-linked polyubiquitination of RICK and TRAF6

To verify the results of the above overexpression studies of IRF4 under physiologic conditions, we next investigated whether IRF4 expression induced by NOD2 inhibits K63-linked polyubiquitination of RICK and/or TRAF6 in human DCs.

Taken together, these studies strongly suggest that IRF4 negatively regulates polyubiquitination of RICK and TRAF6 either in cells in which target proteins are being overexpressed and are being activated by NLR or TLR ligands, respectively.

Figure 4

Mucosal Immunology | Volume 7 Number 6 | November 2014

1317

ARTICLES

Mucosal Immunology | Volume 7 Number 6 | November 2014

1317

ARTICLES
physiologic human DCs, MDP activation of NOD2 and generation of IRF4 result in subsequent inhibition of MDP-induced RICK K63-linked polyubiquitination and LPS-induced TRAF6 K63-linked polyubiquitination. They thus fully corroborate the overexpression studies conducted with 293 cells.

As K63-polyubiquitination of RICK and TRAF6 have been shown to be necessary for TLR-NLR activation of NF-κB, we next asked whether downregulation of IRF4 expression by exposure to IRF4 siRNA also results in reversal of MDP pretreatment-induced inhibition of NF-κB activation. As shown in Figure 6d, culture of DCs in the presence of IRF4 siRNA did in fact abolish the capacity of MDP pretreatment to inhibit either MDP or LPS induction of NF-κB activation as assessed by expression of phospho-IκBα, whereas control siRNA had no effect on inhibition. These results strongly suggest that IRF4 inhibition of RICK and TRAF6 K63-linked polyubiquitination results in downstream inhibition of NF-κB activation.

**Administration of MDP protects mice from trinitrobenzene sulfonic acid (TNBS) colitis via regulation of K63-linked polyubiquitination of RICK and TRAF6**

The above results derived from *in vitro* studies of both 293 cells and human DCs suggest that MDP/NOD2-induced effects on K63-linked polyubiquitination in RICK and TRAF6 could explain our previous studies showing that MDP administration ameliorates experimental colitis. To address this possibility, we next determined the effect of MDP administration on K63-linked polyubiquitination in RICK and TRAF6 in mice with TNBS colitis. As shown in Figure 7a,b, and in the photomicrographs displayed in Supplementary Figure 5a online, systemic administration of MDP protected mice from the induction of TNBS colitis induced by intrarectal instillation of TNBS, and such protection was accompanied by reduced nuclear translocation of NF-κB subunits (p65, p50, and c-Rel) in colonic lamina propria mononuclear cells (LPMCs).

Importantly, several IRF4-related effects accompanied this MDP-mediated protection from colitis. Thus, as shown in Figure 7c, MDP administration led to markedly enhanced IRF4 expression in colonic tissue of MDP-treated mice and, as shown in Figure 7d, Duolink assays revealed that such administration also caused enhanced interaction between IRF4 and RICK, MyD88, or TRAF6 in such colonic tissue. Furthermore, as shown in Figure 7e, MDP administration led to reduced K63-linked polyubiquitination of RICK and TRAF6 in colonic LPMCs that was unaccompanied by reduced K48-linked polyubiquitination. These *in vivo* studies are therefore consistent with the *in vitro* studies described above in showing that MDP-induced IRF4 expression and inhibition of K63-linked polyubiquitination of RICK and TRAF6 is associated with a downregulation of NF-κB; however, in this case, they show that this IRF4 effect is also associated with greatly reduced colonic inflammation.

**Prevention of TNBS colitis by administration of IRF4-expressing plasmids**

Whereas the above studies show that MDP-induced upregulation of IRF4 and the latter’s effect on K63-linked ubiquitination of RICK and TRAF6 is associated with downregulation of NF-κB and colitis, it remained possible that MDP inhibition of NF-κB activation was occurring through another mechanism that does not involve IRF4. To address this possibility we conducted further *in vivo* studies in which we explored the possibility that exogenous IRF4 administration can directly prevent TNBS colitis, thereby by-passing MDP stimulation.
Accordingly, we administered a FLAG-tagged IRF4 plasmid as well as a control plasmid encapsulated in a Hemagglutinin Virus of Japan-Envelope (HVJ-E) viral coat to mice by intrarectal instillation on each of the 2 days before and on the day of intrarectal challenge with TNBS. This method of inducing in vivo protein expression following plasmid administration had proven to be highly efficient in previous studies and, indeed, most of the colonic LPMCs expressing CD11b or CD11c were positive for the expression of FLAG-IRF4 in flow cytometric analysis 2 days after the induction of TNBS colitis (Supplementary Figure S2). As shown in Figure 8a and Supplementary Figure S1b, intrarectal administration of FLAG-tagged IRF4 plasmids prevented the development of TNBS colitis as assessed by body weight loss and colonic pathology analysis. Thus, exogenous IRF4 administration, like MDP administration, is an effective inhibitor of TNBS colitis.

In further studies, we investigated the interaction between the exogenously administered FLAG-tagged IRF4 and RICK, TRAF6, and MyD88 in the colonic mucosa of the mice subjected to intrarectal TNBS challenge accompanied by IRF4 administration. To this end, whole protein extracts isolated from the colonic mucosa were subjected to IP with FLAG Ab and then IB with Abs specific for RICK, TRAF6, and MyD88. As shown in Figure 8b, administered FLAG-tagged IRF4 was bound to RICK, MyD88, and TRAF6. In a final set of studies we determined the effect of the exogenously administered IRF4 on NF-κB and MAP kinase expression as well as on downstream proinflammatory cytokine expression. As shown in Figure 8c,d, exogenously administered IRF4 led to markedly reduced expression of phospho-IκBα, phospho-p38, and phospho-ERK, as well as reduced nuclear translocation of NF-κB bound to RICK, TRAF6, and MyD88.

![Figure 6](image_url)  
**Figure 6** IRF4 expression induced by MDP activation of NOD2 inhibits K63-linked polyubiquitination of RICK and TRAF6. (a) Human monocyte-derived dendritic cells (DCs) were generated as described in Figure 1. DCs (1 × 10^6 per ml) were pretreated with MDP (10 μg ml^-1) for 2 h and then were stimulated with MDP (10 μg ml^-1) or LPS (1 μg ml^-1) for 30 min. Whole-cell lysates were subjected to immunoprecipitation (IP) with the indicated antibody (Ab) followed by immunoblotting (IB) with the indicated Ab. (b) Human DCs were transfected with IRF4-specific siRNA or control siRNA (100 nM). At 1 day after transfection, DCs (1 × 10^6 per ml) were treated with MDP (10 μg ml^-1) for 24 h and then cell lysates were subjected to IP with the indicated Ab. (c) Human DCs were transfected with IRF4-specific siRNA or control siRNA (100 nM). At 1 day after transfection, DCs (1 × 10^6 per ml) were pretreated with MDP (10 μg ml^-1) for 24 h followed by treatment with MG132 (10 μg ml^-1) for 2 h and then were stimulated with MDP (10 μg ml^-1) or LPS (1 μg ml^-1) for 30 min; whole-cell lysates were subjected to IP with the indicated Ab. (d) Human DCs were transfected with IRF4-specific siRNA or control siRNA (100 nM). At 1 day after transfection, DCs (1 × 10^6 per ml) were pretreated with MDP (10 μg ml^-1) for 24 h and then were stimulated with MDP (10 μg ml^-1) or LPS (1 μg ml^-1) for 30 min; whole-cell lysates were subjected to IP with the indicated Ab. Results shown are representative of two experiments. IRF4, interferon regulatory factor 4; LPS, lipopolysaccharide; MDP, muramyl dipeptide; NOD2, nucleotide-binding oligomerization domain 2; RICK, receptor interacting serine–threonine kinase; siRNA, small interfering RNA; TRAF6, tumor necrosis factor receptor associated factor 6.
colonic LPMCs. Thus, as shown in Figure 8e,f, colonic LPMCs produced markedly less IL-12p40 and interferon-γ upon stimulation with MDP, Pam3CSK4 (PAM, a TLR2 ligand), LPS, flagellin (a TLR5 ligand), CpG (a TLR9 ligand), and anti-CD3 Ab.

Taken together, these data show that IRF4 administration mimics the effect of MDP administration and increased NOD2 signaling during induction of TNBS colitis as previously reported.14 As such, they show that prevention of TNBS colitis by MDP administration is most likely acting via the induction of IRF4.

Treatment of TNBS colitis by administration of IRF4-expressing plasmids

The striking effect of IRF4-expressing plasmid administration on TNBS colitis shown above suggested that such administration could have therapeutic value. To address this possibility, we determined whether administration of IRF4-expressing plasmid could reverse previously established TNBS colitis. Accordingly, mice were challenged with TNBS as described above but in this case they were administered FLAG-tagged IRF4 plasmid encapsulated in the HVJ-E vector 3 days after TNBS administration rather than at the time of TNBS administration. As shown in Figure 9a, expression of FLAG was again shown to be present in the colonic mucosa of mice following FLAG-tagged IRF4 plasmid administration. In addition, as shown in Figure 9b and Supplementary Figure S1c, such mice promptly regained body weight and exhibited improved microscopic inflammation scores. Moreover, as shown in Figure 9c–e, administration of IRF4 was followed by reduced nuclear translocation of NF-κB components in the colonic mucosa as well as greatly decreased production of proinflammatory cytokines by mesenteric lymph node cells upon stimulation with TLR ligands and anti-CD3 monoclonal
on day 0. (a) Activation of NF-κB and MAPK in the colon tissues of TNBS-challenged mice on day 2. Two colon extracts from each group were used for the assay. (b) Interaction between FLAG-tagged IRF4 and RICK, MyD88, and TRAF6 in the colonic tissue of mice. Whole protein lysates were prepared from the colon tissues of TNBS-challenged mice on day 2 and were subjected to immunoprecipitation (IP) with the indicated antibody (Ab) followed by immunoblotting (IB) with the indicated Ab. Two colon extracts from each group were used for the assay. (c) Changes in body weight in mice (n = 5; each group, top panel) and pathology scores of mice on day 4. Results were expressed as means ± s.d. **P < 0.01 as compared with control vector group. (d) NF-κB activation in colon tissues in mice challenged with TNBS. Nuclear extracts were isolated from colon tissues on day 2 and subjected to a TransFactor Binding Assay. Results were expressed as means ± s.d. **P < 0.01 as compared with control vector group. (e) Production of IL-12p40 and interferon-γ (IFN-γ) by colon LPMCs isolated from TNBS-challenged mice on day 4. Colon LPMCs (1 × 10⁶ per ml) were stimulated with MDP, PAM, LPS, Flagellin, and CpG for 24 h or with anti-CD3 Ab for 48 h after which culture fluids were assayed for IL-12p40 or IFN-γ levels by enzyme-linked immunosorbent assay (ELISA), as indicated. Results were expressed as means ± s.d. **P < 0.01 as compared with group-administered control vector. Results shown are representative of two experiments. HVJ, hemagglutinin virus of Japan; IL, interleukin; IRF4, interferon regulatory factor 4; LPMC, lamina propria mononuclear cell; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; MDP, muramyl dipeptide; MyD88, myeloid differentiation factor 88; NF-κB, nuclear factor-kB; RICK, receptor interacting serine–threonine kinase; TRAF6, tumor necrosis factor receptor associated factor 6.

Ab. These data thus provide further proof that MDP activation of NOD2 and generation of IRF4 leads to downregulation of NF-κB activation and colonic inflammation. In addition, they suggest that IRF4 administration might have clinical value.

**DISCUSSION**

In a previous study, we demonstrated that MDP activation of NOD2 has downregulatory effects on multiple TLR signaling pathways.¹⁴ We now provide a mechanism for such downregulation by showing that MDP activation of NOD2 induces IRF4-mediated inhibition of molecular events essential to the activation of NF-κB, namely K63-linked polyubiquitination of RICK and TRAF6. The chain of evidence supporting this conclusion consisted first of the fact that MDP prestimulation of human DCs leads to binding of RICK to IRF4 and the binding of IRF4 to TRAF6 and MyD88. As shown in overexpression studies conducted in a cell line and more importantly in physiologic human DCs, these interactions set the stage for MDP/NOD2-induced IRF4 inhibition of K63-linked polyubiquitination of RICK and TRAF6; in addition, such inhibition could be linked to downregulation of NF-κB activation by the demonstration that siRNA downregulation of IRF4 reverses the negative effect by NOD2 signaling on K63-linked polyubiquitination and NF-κB activation. These *in vitro* studies were then supported by *in vivo* studies showing that protection from the development of TNBS colitis by MDP administration is accompanied by greatly increased IRF4 expression and interaction with RICK, TRAF6, and MyD88, as well as inhibition of K63-linked polyubiquitination of RICK and TRAF6 in colonic cells and this, in turn, is associated with...
greatly reduced NF-κB activation. A final step in the chain of evidence consisted of studies showing that administration of an IRF4-expressing plasmid to mice both prevented TNBS colitis and reversed already established TNBS colitis. These latter studies established that MDP activation of NOD2 in vivo was in fact acting via IRF4 to inhibit NF-κB activity. Overall, these data provide a mechanistic explanation of how MDP–NOD2 stimulation of APCs negatively regulates inflammatory responses induced by TLR ligands and therefore explain how defective NOD2 function can lead to excessive TLR responses in the gut that contribute to the pathogenesis of CD.

IRF4 has been shown in previous reports to function as a negative regulator of TLR signaling pathways in innate immune cells such as DCs. As for the mechanisms accounting for such negative regulation, Negishi et al. provided evidence that IRF4 expression is upregulated by activation of TLRs and then competes with IRF5 for binding to and activation of MyD88. Although this mechanism of IRF4 inhibitory activity may be valid, it cannot be the only mechanism in play because we have shown previously as well in the present studies that MDP prestimulation acting through NOD2 inhibits LPS and other TLR ligand cytokine responses, including TLR responses that do not involve MyD88. It should be noted in this context that whereas NOD2 activation leads to RICK–IRF4 binding, LPS activation in the absence of MDP-induced NOD2 interaction does not have this effect (Watanabe, T., Asano, N., and Strober, W., unpublished observation). Thus, it is possible that NOD2 activation leads to RICK–IRF4 complexes that have inhibitory functions not shared by IRF4 alone. In any case, we have shown that systemic administration of MDP to mice...
challenged with TNBS to induce TNBS colitis leads to enhanced expression of IRF4 in colonic LPMCs and inhibition of inflammation due to reduced K63-linked polyubiquitination of TRAF6 and RICK in those cells. In addition, intrarectal administration of an IRF4-expressing plasmid to mice challenged with TNBS had a similar anti-inflammatory effect. Thus, our study disclosed a molecular mechanism by which NOD2-induced IRF4 inhibits intestinal inflammation driven, at least in part, by activation of TLR signaling pathways that are not regulated by TLR-induced IRF4.

In the above studies of TNBS colitis, the development of colitis was inhibited either by systemic injection of MDP or intrarectal administration of IRF4 complementary DNA. These treatments were parallel in that administration of MDP resulted in enhanced interaction between IRF4 and RICK, TRAF6, and MyD88, and administration of IRF4 complementary DNA led to interaction of IRF4 with the same signaling molecules; moreover, reduction of NF-κB activation was seen in both treatments. Thus, it is likely that MDP activation of NOD2 prevents experimental colitis via induction of IRF4 expression. It should be noted that this conclusion leads to the assumption that activation of TLRs with the ability to induce the expression of IRF4 have the potential to inhibit experimental colitis via the same deubiquitination mechanism described here for NOD2. However, previous reports show that generation of tolerogenic responses by LPS depends upon the induction of IRAK-M (IL-1 receptor-associated kinase M) rather than IRF4.\textsuperscript{13,20} Thus, tolerogenic responses induced by MDP administration of NOD2 appear to be intrinsically different from those induced by LPS activation of TLR4, and although LPS administration may suppress colitis because of induction of LPS tolerance, such suppression will not be mediated by the deubiquitination function of IRF4.

Of interest, IRF4 may be exerting inhibitory effects by a mechanism similar to that described here in other instances of proinflammatory responses. This includes IRF4-mediated suppression of TLR-induced cytokine responses, leading to acute postischemic renal inflammation by IRF4 generated in renal DCs reacting to oxidative stress.\textsuperscript{30} and IRF4-mediated reduction of TLR-induced proinflammatory responses of liver plasmacytoid DCs by IRF4 generated in such cells by in vivo administration of MDP.\textsuperscript{13} However, additional studies will be necessary to verify this possibility.

IRF4 is expressed in most types of cells in the lymphoid system and may have cell-specific functions.\textsuperscript{31} This possibility is illustrated by the fact that, in contrast to the anti-inflammatory role of IRF4 in TNBS colitis and postischemic renal inflammation described above, it has a proinflammatory role in experimental T cell-mediated autoimmune disorders.\textsuperscript{31} The latter may be because of the fact that IRF4 has been shown to be a positive regulator of IL-17 and IL-21 responses in T cells and it increased responsiveness to IL-21 in B cells.\textsuperscript{22,31,32} Interestingly, there is evidence that this proinflammatory activity by IRF4 plays a critical role in a T cell-dependent colitis. Thus, Mudter et al.\textsuperscript{33,34} have shown that adoptive transfer of naïve CD4\textsuperscript{+} T cells from WT mice, but not IRF4-deficient mice, to immune-deficient mice resulted in severe colitis associated with increased production of IL-6 and T helper type 17 cytokines. In our studies, intrarectal delivery of a plasmid expressing FLAG-tagged IRF4 was shown to lead to marked expression of FLAG-tagged IRF4 in colonic APCs rather than in colonic T cells. Thus, our data support the idea that whereas IRF4 expression in T cells may promote the development of colitis, its expression in APCs has the contrary effect. In this context, it should also be noted that the HVJ-E delivery of IRF4-expressing plasmid could have led to IRF4 expression in nonmyeloid cells, and thus we cannot rule out the possibility that the ability of exogenous IRF4 expression to affect colitis in these studies could have been mediated by effects on one or another nonmyeloid cell.

As shown by the fact that intrarectal administration of NF-κB decoy oligonucleotides that blocks activation of NF-κB target genes prevents and treats TNBS or oxazolone colitis, the pathogenic immune responses underlying experimental colitis depend on NF-κB transcriptional activity.\textsuperscript{35,36} In recent years, evidence has accumulated that such NF-κB-mediated inflammation is tightly regulated by ubiquitination of various components of the NF-κB signaling cascade. This is well illustrated by the fact that the function of TRAF6, an essential component of the signaling cascade leading to NF-κB activation, is dependent on its K63-linked polyubiquitination status. Thus, deubiquitination of TRAF6 by the deubiquitinating enzyme, A20, leads to inhibition of TLRs-induced NF-κB activation,\textsuperscript{24,37} and A20 deficiency results in excessive NF-κB activation associated with the development of autoimmune disease or colitis due to stimulation by TLR ligands derived from the intestinal microflora.\textsuperscript{24,38} In this study, we show that downregulation of K63-linked polyubiquitination of TRAF6 resulting from an inhibitory interaction with IRF4 also leads to decreased NF-κB activation. The mechanism of such IRF4 inhibition is presently unknown. However, given the fact that TRAF6 is an E3-ligase and can therefore facilitate both the polyubiquitination of downstream signaling molecules and its own polyubiquitination, one possible mechanism is that IRF4 interferes with TRAF6 E3-ligase activity.

Despite the fact that CARD15 polymorphisms associated with CD are considered to be loss-of-function abnormalities that lead to decreased NOD2-mediated proinflammatory function, immune responses linked to CD are characterized by production of proinflammatory cytokines driven by excessive NF-κB activation.\textsuperscript{39,40} One explanation of this paradox is that NOD2 signaling in epithelial cells is necessary for the elaboration of epithelial cell-derived cryptins that ordinarily control bacterial growth in the intestine; thus, loss of NOD2 function can lead to excessive bacterial growth that gives rise to colitis.\textsuperscript{51,42} It should be noted, however, that chronic NOD2 activation has been shown to mediate downregulation of innate TLRs responses to microbial antigens in the intestine, a phenomenon known as cross-tolerance.\textsuperscript{14–17} Therefore, an alternative explanation of how CARD15 polymorphisms and loss of NOD2 function leads to intestinal disease is that NOD2 regulates innate responses to intestinal microflora by suppressing TLR responses in the healthy intestinal mucosa, whereas in the diseased CD intestinal mucosa lack of NOD2 function leads to lack of cross-tolerance and excessive TLR responses. This study together with our previous study of NOD2 signaling
shows that defective NOD2-induced IRF4 inhibitory function is likely to be the cause of the loss of cross-tolerance and thus the molecular basis for the role of loss of NOD2 function in CD.14

In conclusion, the present findings provide evidence that CARD15 polymorphisms function as susceptibility factors in CD by affecting the generation and activation of the factor, IRF4, that plays a key role in the regulation of TLR responses induced by the gut microflora. In addition, they show in studies of mice with experimental colitis that MDP administration leading to colonic IRF4 expression or intrarectal delivery of an IRF4 expression plasmid have the potential to both prevent and treat such colitis and possibly CD as well.

METHODS

Reagents. Recombinant GM-CSF and IL-4 were from Peprotech (Rocky Hill, NJ). Unless otherwise described, the doses of TLR ligands and NOD2 ligands used for stimulation were as follows: Pam3CSK4 (PAM, TLR2 ligand, 10 μg ml⁻¹, InvivoGen, San Diego, CA), LPS (TLR4 ligand, 1 μg ml⁻¹, Sigma, St Louis, MO), flagellin (TLR5 ligand, 1 μg ml⁻¹, InvivoGen), CpG (TLR9 ligand, 1 μM, InvivoGen), and MDP (NOD2 ligand, 10 μg ml⁻¹, InvivoGen).

Induction of colitis. TNBS colitis was induced in C57BL10 mice obtained from Japan SLC (Hamamatsu, Japan) as described previously.35 On days −2, −1, and 0, mice received intraperitoneal injection of MDP (100 μg) for a total of three times before intrarectal administration of 3.75 mg of TNBS in 100 μl of 45% ethanol. Mesenteric lymph node cells and colon LPMCs were isolated at the indicated time points and cultured as described previously.14 Cells were stimulated with anti-CD3 (1 μg ml⁻¹, BD Pharmingen, San Jose, CA) and TLR ligands as described above. Culture supernatants were collected at 24 or 48 h and analyzed for cytokine production by enzyme-linked immunosorbent assay (ELISA). In some experiments, whole-cell extracts were prepared from colon tissue or LPMCs for the enzyme-linked immunosorbent assay (ELISA). In some experiments, whole-cell lysates were prepared 24 or 48 h after the transfection and were incubated with anti-FLAG conjugated beads (Sigma), anti-V5 conjugated beads (Sigma), and anti-HA-conjugated beads (Sigma) overnight. In some experiments, whole-cell lysates prepared from human DCs, colonic LPMCs, and colon tissue samples were incubated with anti-K63 Ub Ab, anti-K48 Ub Ab (MBL, Nagoya, Japan) or anti-IRF4 Ab (Santa Cruz Biotechnology, Santa Cruz, CA) and protein A/G agarose (Santa Cruz Biotechnology). Anti-MyD88, anti-TRAF6, anti-IRF4, anti-IκBα, anti-phospho-IRF4, anti-phospho-p38, anti-phospho-ERK, anti-ERK, and anti-His Abs were obtained from Cell Signaling Technology (CST; Danvers, MA). Anti-actin Ab (Santa Cruz), anti-RICK Ab (Cayman Chemicals, Ann Arbor, MI), anti-V5 Ab (Bethyl Laboratories, Montgomery, TX), anti-FLAG Ab (Sigma), anti-HA Ab (Sigma), and anti-Myc Ab (MBL) were used.

Immunofluorescence studies. Colon tissues were harvested and fixed in 10% formalin. Deparaffinized colon sections were then obtained and incubated with mouse anti-IRF4 Ab (Invitrogen) followed by Alexa 546-conjugated anti-mouse IgG Ab (Invitrogen) by using Can Get Signal immunoreaction enhancer solution (Toyobo, Osaka, Japan) as described previously.35 For visualization of interaction between IRF4 and RICK, MyD88, and TRAF6 in colon samples, a Duolink In Situ kit was used (Olink Bioscience, Uppsala, Sweden). Goat anti-IRF4 Ab (Santa Cruz), rabbit anti-RICK Ab, rabbit anti-MyD88 Ab, and rabbit anti-TRAF6 Ab (Abcam, Cambridge, MA) were used to visualize target protein interactions. For visualization of interaction between IRF4 and RICK, MyD88, and TRAF6 in human DCs, cells were fixed in 4% paraformaldehyde and subjected to the protocols suggested by the Duolink In Situ kit.

ELISA. Protein concentrations of cytokines were determined by eBioscience (San Diego, CA) ELISA kits for mouse IL-12p40, mouse IL-6, and mouse tumor necrosis factor-α. Concentration of interferon-γ was determined by BD Bioscience (San Jose, CA) ELISA kit.

NF-κB activation studies. Nuclear extracts were prepared from colon tissues. Nuclear extracts were obtained with the use of a nuclear extraction kit (Active Motif, Carlsbad, CA). Binding activity of nuclear extract (5 μg) to NF-κB subunit (p50, p65, and c-Rel) was measured using a Transam kit, obtained from Active Motif, as previously described.14

Statistical analysis. Student’s t-test was used to evaluate the significance of the differences. Statistical analysis was performed with the Prism (Graphpad software, La Jolla, CA). A value of P < 0.05 was regarded as statistically significant.

SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/mi

ACKNOWLEDGMENTS This work was supported by Grant-in-Aid for Scientific Research (25293172, 21229009, 24229005, and 24659363) from the Japan Society for the Promotion of Science, the Japanese Society of Gastroenterology, and the Special Coordination Funds by the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Astellas Pharma in Creation of Innovation Centers for Advanced Interdisciplinary Research Areas.
REFERENCES

1. Strober, W. & Watanabe, T. NOD2, an intracellular innate immune sensor involved in host defense and Crohn’s disease. Mucosal Immunol. 4, 484–495 (2011).

2. Strober, W., Murray, P.J., Kitani, A. & Watanabe, T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat. Rev. Immunol. 6, 9–20 (2006).

3. Inohara, H., Chamaillard, M., McDonald, C. & Nunez, G. NOD-LPR proteins: role in host-microbial interactions and inflammatory disease. Annu. Rev. Biochem. 74, 355–383 (2005).

4. Abbott, D.W., Wilkins, A., Asara, J.M. & Cantley, L.C. The Crohn’s disease protein, NOD2, requires RIP2 in order to induce ubiquitylation of a novel site on NEMO. Curr. Biol. 14, 2217–2224 (2004).

5. Abbott, D.W., Yang, Y., Hutti, J.E., Madhavarapu, S., Kelliher, M.A. & Cantley, L.C. Coordinated regulation of Toll-like receptor and NOD2 signalling by K63-linked polyubiquitin chains. Mol. Cell. Biol. 27, 6012–6023 (2007).

6. Bertrand, M.J., Doiron, K., Labbe, K., Korneluk, R.G., Barker, P.A. & Saleh, M. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity. 30, 789–801 (2009).

7. Hasegawa, M. et al. Critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J. 27, 373–383 (2008).

8. Kim, Y.G., Park, J.H., Shaw, M.H., Franchi, L., Inohara, N. & Nunez, G. The cytosolic sensors Nod1 and Nod2 are critical for bacterial recognition and host defense after exposure to Toll-like receptor ligands. Immunity. 28, 246–257 (2008).

9. Cho, J.H. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 8, 458–466 (2008).

10. Tada, H., Aiba, S., Shibata, K., Ohteki, T. & Takada, H. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect. Immun. 73, 7967–7976 (2005).

11. van Heel, D.A. et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn’s disease. Lancet 365, 1794–1796 (2005).

12. Werts, C., Rubino, S., Ling, A., Girardin, S.E. & Philpott, D.J. Nod-like protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel protein, NOD2/RICK/TAK1 pathway and activates caspase-1 to induce intestinal barrier dysfunction. Cell Host Microbe 11, 337–351 (2012).

13. Watanabe, T. et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J. Clin. Invest. 118, 545–559 (2008).

14. Hedl, B.J. et al. Crohn’s disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Gastroenterology 140, 231–241 (2010).

15. Kulberg, B.J. et al. Crohn’s disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Gastroenterology 140, 231–241 (2010).

16. Hedl, B.J. & Abraham, C. Secretory mediators regulate Nod2-induced tolerance in human macrophages. Gastroenterology 140, 231–241 (2010).

17. Muller, B.J. et al. Crohn’s disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Gastroenterology 140, 231–241 (2010).

18. Yeretsian, G. et al. Non-apoptotic role of BID in inflammation and innate immunity. Nature 474, 96–99 (2011).

19. Meinzer, U. et al. Yersinia pseudotuberculosis effector YopJ subverts the Nod2/RICK/TAK1 pathway and activates caspase-1 to induce intestinal barrier dysfunction. Cell Host Microbe 11, 337–351 (2012).

20. Nembrini, C. et al. The kinase activity of Rip2 determines its stability and consequently Nod1- and Nod2-mediated immune responses. J. Biol. Chem. 284, 19183–19188 (2009).

21. Dorsch, M. et al. Identification of a regulatory autophosphorylation site in the serine-threonine kinase RIP2. Cell. Signal. 18, 2223–2229 (2006).

22. Biswas, P.S. et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J. Clin. Invest. 120, 3290–3296 (2010).

23. Natkunam, Y., Warnke, R.A., Montgomery, K., Falini, B. & van De Rijn, M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod. Pathol. 14, 686–694 (2001).

24. Chen, Z. Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol. 7, 758–765 (2005).

25. Tao, M., Scacheri, P.C., Marinis, J.M., Harhaj, E.W., Matesic, L.E. & Abbott, D.W. ITCH KG3-ubiquitinites the NOD2 binding protein, RIP2, to influence inflammatory signalling pathways. Curr. Biol. 19, 1255–1263 (2009).

26. Yang, Y., Yin, C., Pandey, A., Abbott, D., Sassetti, C. & Kelliher, M.A. NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J. Biol. Chem. 282, 36223–36229 (2007).

27. Akira, S. & Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499–511 (2004).

28. Negishi, H. et al. Negative regulation of Toll-like-receptor signaling by IFR4. Proc. Natl. Acad. Sci. USA 102, 15899–15904 (2005).

29. Homma, K. et al. Interferon regulatory factor 4 negatively regulates the production of proinflammatory cytokines by macrophages in response to LPS. Proc. Natl. Acad. Sci. USA 102, 16001–16006 (2005).

30. Lassen, S., Lech, M., Rommele, C., Mittreucker, H.W., Mek, T.W. & Anders, H.J. Ischemia-reperfusion induces IFN regulatory factor 4 in renal dendritic cells, which suppresses postischemic inflammation and prevents acute renal failure. J. Immunol. 185, 1976–1983 (2010).

31. Xu, W.D., Pan, H.F., Ye, D.Q. & Xu, Y. Targeting IRF4 in autoimmune diseases. Autoimmun. Rev. 11, 918–924 (2012).

32. Biswas, P.S. et al. Dual regulation of IRF4 function in Tand B cells is required for the coordination of T-B cell interactions and the prevention of autoimmunity. J. Exp. Med. 209, 581–596 (2012).

33. Muder, J. et al. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J. Clin. Invest. 118, 2415–2426 (2008).

34. Fichtner-Feigl, S., Fuss, I.J., Preiss, J.C., Strober, W. & Kitani, A. Treatment of murine Th1 and Th2-mediated inflammatory bowel disease with NF-kappaB decoy oligonucleotides. J. Clin. Investig. 115, 3057–3071 (2005).

35. De Vry, C.G. et al. Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut 56, 524–533 (2007).

36. Ma, A. & Malynn, B.A. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat. Rev. Immunol. 12, 774–785 (2012).

37. Hammer, G.E. et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthrits. Nat. Immunol. 12, 1184–1193 (2011).

38. Strober, W., Fuss, I.J. & Mannon, P. The fundamental basis of inflammatory bowel diseases. J. Clin. Investig. 117, 514–521 (2007).

39. Strober, W. & Fuss, I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140, 1756–1767, e1751 (2011).

40. Wehkamp, J. et al. The Paneth cell alpha-defensin deficiency of ileal Crohn’s disease is linked to Wnt/Tcf-4. J. Immunol. 179, 3109–3118 (2007).

41. Kobayashi, K.S. et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307, 731–734 (2005).

42. Tsuji, Y., Watanabe, T., Kudo, M., Arai, H., Strober, W. & Chiba, T. Sensing of commensal organisms by the intracellular sensor NOD1 mediates experimental pancreatitis. Immunity 37, 326–338 (2012).